drugset / Trial / NCT01249001
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
RandomizedCrossoverOpen-labelTreatment
Summary
The primary objective of this study is to compare the absorption of a prepared aprepitant oral suspension with that of the aprepitant capsule in children being treated with chemotherapy agents that are likely to cause vomiting.
Timeline
- Start
- 2010-10
- Primary completion
- 2016-09-28
- Completion
- 2016-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 125 mg | Oral |
Indications
No indication recorded.